Where to find opportunities amid the trade war turmoil
We explore whether it might be time to buy the likes of CBA (ASX:CBA), BHP Group (ASX:BHP), Santos (ASX:STO), and Woodside (ASX:WDS).
Market Cap $61.53M
!
Corporate Spotlight
Neurizon Therapeutics Limited (ASX: NUZ) is a clinical-stage biotechnology company dedicated to advancing treatments for neurodegenerative diseases. Neurizon is developing its lead drug candidate, NUZ-001, for the treatment of ALS, which is the most common form of motor neurone disease.
View the full Corporate Spotlight
NUZ ANNOUNCES STRONG RESULTS IN LATEST STUDY
| Day | ||||||||
|---|---|---|---|---|---|---|---|---|
| Open | 12.0¢ | Day High | 13.0¢ | Day Low | 12.0¢ | |||
| Daily Volume | 368601 | |||||||
| Bids | Sellers | |||||
|---|---|---|---|---|---|---|
| Number | Price | Volume | Number | Price | Volume | |
| 1 | 12.5¢ | 457783 | 5 | 13.0¢ | 266325 | |
Directors & Senior Management
| Dr. Michael Thurn | Chief Executive Officer, Managing Director, Director |
| Mr. John Clark | Chief Operating Officer |
| Dr. Nicky Wallis | Chief Scientific Officer |
| Ms. Fiona Milner | General Manager - Epichem Pty Ltd |
| Mr. Stefan Ross | Company Secretary |
| Mr. Sergio Duchini | Non-Executive Chairman of the Board |
| Mr. Marcus Paul Hughes | Non-Executive Director |
| Dr. Kathryn Macfarlane | Non-Executive Director |
Data source: Refinitiv
 (20min delay)
|
|||||
|
Last
12.5¢ |
Change
0.015(13.6%) |
Mkt cap ! $61.53M | |||
| Open | High | Low | Value | Volume |
| 12.0¢ | 13.0¢ | 12.0¢ | $45.40K | 368.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 457783 | 12.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 13.0¢ | 266325 | 5 |
View Market Depth
| Last trade - 16.10pm 23/04/2025 (20 minute delay) ? |
| NUZ (ASX) Chart |
